ENTBF
Price
$0.20
Change
-$0.00 (-0.00%)
Updated
Jan 16 closing price
Capitalization
1.66M
SER
Price
$4.81
Change
+$0.06 (+1.26%)
Updated
Jan 17 closing price
Capitalization
45.18M
Ad is loading...

ENTBF vs SER

Header iconENTBF vs SER Comparison
Open Charts ENTBF vs SERBanner chart's image
ENTHEON BIOMEDICAL
Price$0.20
Change-$0.00 (-0.00%)
Volume$1.02K
Capitalization1.66M
Serina Therapeutics
Price$4.81
Change+$0.06 (+1.26%)
Volume$41.48K
Capitalization45.18M
ENTBF vs SER Comparison Chart
Loading...
View a ticker or compare two or three
VS
ENTBF vs. SER commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTBF is a Hold and SER is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ENTBF: $0.20 vs. SER: $4.81)
Brand notoriety: ENTBF and SER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTBF: 36% vs. SER: 133%
Market capitalization -- ENTBF: $1.66M vs. SER: $45.18M
ENTBF [@Biotechnology] is valued at $1.66M. SER’s [@Biotechnology] market capitalization is $45.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTBF’s FA Score shows that 0 FA rating(s) are green whileSER’s FA Score has 1 green FA rating(s).

  • ENTBF’s FA Score: 0 green, 5 red.
  • SER’s FA Score: 1 green, 4 red.
According to our system of comparison, SER is a better buy in the long-term than ENTBF.

Price Growth

ENTBF (@Biotechnology) experienced а +3.38% price change this week, while SER (@Biotechnology) price change was +1.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

SER is expected to report earnings on Mar 31, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
SER($45.2M) has a higher market cap than ENTBF($1.66M). ENTBF YTD gains are higher at: 49.097 vs. SER (-3.992). SER has more cash in the bank: 3.19M vs. ENTBF (229K).
ENTBFSERENTBF / SER
Capitalization1.66M45.2M4%
EBITDA-323.3KN/A-
Gain YTD49.097-3.992-1,230%
P/E RatioN/A30.41-
Revenue0N/A-
Total Cash229K3.19M7%
Total DebtN/A11.5M-
FUNDAMENTALS RATINGS
SER: Fundamental Ratings
SER
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
24
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

ENTBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTBF has been loosely correlated with SPRB. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTBF jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTBF
1D Price
Change %
ENTBF100%
N/A
SPRB - ENTBF
38%
Loosely correlated
-4.75%
SER - ENTBF
35%
Loosely correlated
+1.26%
IMRX - ENTBF
31%
Poorly correlated
+3.06%
XTLB - ENTBF
29%
Poorly correlated
-6.21%
GERN - ENTBF
27%
Poorly correlated
-1.03%
More

SER and

Correlation & Price change

A.I.dvisor indicates that over the last year, SER has been closely correlated with GERN. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if SER jumps, then GERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SER
1D Price
Change %
SER100%
+1.26%
GERN - SER
68%
Closely correlated
-1.03%
XTLB - SER
59%
Loosely correlated
-6.21%
ELVN - SER
37%
Loosely correlated
-2.36%
ENTBF - SER
35%
Loosely correlated
N/A
TOVX - SER
34%
Loosely correlated
+3.50%
More